BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
- Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Mayo Clinic
Jacksonville, Florida, United States
- Memorial Healthcare System
Pembroke Pines, Florida, United States
- Emory University Winship Cancer Institute
Atlanta, Georgia, United States
- the University of Chicago
Chicago, Illinois, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Hackensack University Medical Center
Hackensack, New Jersey, United States
- Mount Sinai Medical Center
New York, New York, United States
- University of Texas Health Science Center
San Antonio, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Jul 2012
- Primary completion
- 30 Oct 2018
- Completion
- 30 Oct 2018
- Last update posted
- 23 Jul 2019
- Registered enrollment
- 64
- Registry id
- NCT01638936
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.